Methods for treating brain swelling with a compound that blocks a non-selective cation channel
The present invention is directed to therapeutic compounds, treatment methods, and kits affecting the NC Ca-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system, and methods of using same. The NC Ca-ATP channel is newly expressed in neural tissue following injury such as ischemia, and is regulated by the sulfonylurea receptor SUR1, being inhibited by sulfonylurea compounds, e.g., glibenclamide and tolbutamide, and opened by diazoxide. Antagonists of the NC Ca-ATP channel, including SUR1 antagonists, are useful in the prevention, diminution, and treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury. Agonists of the NC Ca-ATP channel may be are useful in the treatment neural tissue where damage or destruction of the tissue, such as a gliotic capsule, is desired.
1. A method of ameliorating the effect of a reduction in blood flow in peri-infarct brain tissue in ischemic disease or injury in a subject comprising administering to a subject having a reduction in blood flow in peri-infarct brain tissue in ischemic disease or injury an amount of a compound that is effective to inhibit the activity of a NC Ca-ATP channel in a neuronal cell, a neuroglia cell, or a neural endothelial cell and that is effective to ameliorate the effect of a reduction in blood flow in peri-infarct brain tissue in ischemic disease or injury, wherein the compound is a sulfonylurea compound, a benzamido derivative, an imidazoline derivative, or a combination thereof, and wherein the effect of said reduction in said blood flow in peri-infarct brain tissue in said ischemic disease or said injury in the subject is ameliorated.
2. The method of claim 1 , where said compound is a compound capable of effecting hypoglycemia in said subject, further comprising administration of glucose to said subject effective to at least partially ameliorate said hypoglycemic effects in said subject.
3. The method of claim 1 , wherein the amelioration of the effect of a reduction in blood flow comprises a reduction in cytotoxic edema, ionic edema, vasogenic edema, or a combination thereof.
4. The method of claim 1 , wherein the neuroglia cell is selected from the group consisting of astrocyte, ependymal cell, oligodentrocyte and microglia.
5. The method of claim 1 , wherein the compound effective to inhibit a NC Ca-ATP channel is administered alimentarily, parenterally, topically, mucosally, or by injection into brain parenchema.
6. The method of claim 1 , wherein said sulfonylurea compound is selected from the group consisting of glibenclamide, tolbutamide, gliclazide, and glimepiride.
7. The method of claim 1 , wherein said benzamido derivative is selected from the group consisting of repaglinide, nateglinide, and meglitinide.
8. The method of claim 1 , wherein said imidazoline derivative is selected from the group consisting of LY397364 and LY389382.
9. The method of claim 1 , wherein the compound effective to inhibit the NC Ca-ATP channel is administered parenterally, topically, or mucosally.
10. The method of claim 1 , further comprising administering glucose to said subject.
11. A method of inhibiting neuronal cell swelling in the brain of a subject, said method comprising administering to a subject having neuronal cell swelling in the brain a formulation comprising an amount of a compound that is effective to block a NC Ca-ATP channel and that is effective to inhibit neuronal cell swelling, wherein the compound is a sulfonylurea compound, a benzamido derivative, an imidazoline derivative, or a combination thereof, and a pharmaceutically acceptable carrier, and wherein said neuronal cell swelling in the brain of the subject is inhibited.
12. The method of claim 11 , wherein said inhibiting neuronal cell swelling is further defined as preventing neuronal cell swelling.
13. The method of claim 11 , where said formulation comprises a compound capable of effecting hypoglycemia in said subject, further comprising administration of glucose to said subject effective to at least partially ameliorate said hypoglycemic effects in said subject.
14. The method of claim 13 , wherein said inhibiting neuronal cell swelling is further defined as preventing neuronal cell swelling.
15. The method of claim 11 , further comprising administering glucose to said subject.
16. A method of alleviating brain swelling in a subject, comprising administering to the subject a formulation comprising an amount of a compound that is effective to block a NC Ca-ATP channel and that is effective to alleviate brain swelling in the subject, wherein the compound is a sulfonylurea compound, a benzamido derivative, an imidazoline derivative, or a combination thereof and a pharmaceutically acceptable carrier, and wherein said brain swelling in the subject is alleviated.
17. The method of claim 16 , where said formulation is a formulation capable of effecting hypoglycemia in said subject, further comprising administration of glucose to said subject effective to at least partially ameliorate said hypoglycemic effects in said subject.
18. The method of claim 16 , further comprising administering glucose to said subject.
19. A method of treating acute cerebral ischemia in a subject comprising administering to a subject having acute cerebral ischemia an amount of a compound that is effective to inhibit a NC Ca-ATP channel and that is effective to treat acute cerebral ischemia, wherein the compound is a sulfonylurea compound, a benzamido derivative, an imidazoline derivative, or a combination thereof, or a pharmaceutically acceptable salt thereof, and wherein said acute cerebral ischemia in the subject is treated.
20. The method of claim 19 , wherein the NC Ca-ATP channel is expressed on neuronal cells, neuroglia cells, neural endothelial cells or a combination thereof.
21. The method of claim 19 , wherein said sulfonylurea compound is selected from the group consisting of glibenclamide, tolbutamide, and glimepiride.
22. The method of claim 19 , wherein the mode of administration of said NC Ca-ATP channel inhibitor is selected from the group of modes of administration consisting of bolus injection, infusion, and bolus injection in combination with an infusion.
23. The method of claim 19 , wherein said NC Ca-ATP channel inhibitor is glibenclamide.
24. The method of claim 19 , further comprising administering glucose to said subject.
25. The method of claim 19 , wherein the compound effective to inhibit a NC Ca-ATP channel is administered alimentarily, parenterally, topically, mucosally, or by injection into brain parenchema.
26. The method of claim 19 , wherein said benzamido derivative is selected from the group consisting of repaglinide, nateglinide, and meglitinide.
27. The method of claim 19 , wherein said imidazoline derivative is selected from the group consisting of LY397364 and LY389382.
28. A method of alleviating one or more effects of traumatic brain injury or cerebral ischemia stemming from neural cell swelling in a subject, comprising administering to a subject having traumatic brain injury or cerebral ischemia stemming from neural cell swelling a formulation comprising an amount of a compound that is effective to block a NC Ca-ATP channel and that is effective to alleviate one or more of the effects of traumatic brain injury or cerebral ischemia, wherein the compound is a sulfonylurea compound, a benzamido derivative, an imidazoline derivative, or a combination thereof, glucose, and a pharmaceutically acceptable carrier, and wherein one or more effects of said traumatic brain injury or said cerebral ischemia stemming from said neural cell swelling in the subject is alleviated.
29. The method of claim 28 , further comprising administering glucose to said subject.
30. A method of alleviating one or more effects of traumatic brain injury or cerebral ischemia in a subject, comprising administering to a subject having traumatic brain injury or cerebral ischemia a formulation comprising an amount of a sulfonylurea compound that is effective to alleviate one or more effects of traumatic brain injury or cerebral ischemia and a pharmaceutically acceptable carrier, and wherein one or more effects of said traumatic brain injury or said cerebral ischemia in the subject is alleviated.
31. A method of treating acute cerebral ischemia in a subject, comprising:
determining an appropriate amount of a compound that inhibits a NC Ca-ATP channel in a subject needing treatment for acute cerebral ischemia, wherein the compound is a sulfonylurea compound, a benzamido derivative, an imidazoline derivative, or a combination thereof, or a pharmaceutically acceptable salt thereof; and
administering the compound to the subject, wherein said acute cerebral ischemia in the subject is treated.
32. A method of alleviating one or more effects of traumatic brain injury or cerebral ischemia in a subject, comprising:
determining an appropriate amount of a formulation for a subject, wherein the formulation comprises an effective amount of a sulfonylurea compound and a pharmaceutically acceptable carrier, and
administering the formulation to the subject, wherein one or more effects of said traumatic brain injury or said cerebral ischemia in the subject is alleviated.